| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8775948 | Urology | 2018 | 27 Pages |
Abstract
Among patients with mCRPC, we failed to show any increased risk of hospitalizations and ER visits for treatment-related complications for abiraterone or enzalutamide. In contrast, treatment with intravenous chemotherapeutic agents was associated with an increased risk of hospitalizations and ER visits to manage these complications.
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Christopher J.D. Wallis, Raj Satkunasivam, Refik Saskin, Symron Bansal, Girish S. Kulkarni, Urban Emmenegger, Robert K. Nam,